CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ZS Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ZS Pharma Inc
508 Wrangler Dr Ste 100
Phone: (650) 458-4100p:650 458-4100 COPPELL, TX  75019-7609  United States Fax: (650) 362-9575f:650 362-9575

This company was Merged or Acquired on 12/17/2015.
This company ceased filing statements with the SEC on 12/28/2015.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
ZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company's zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. The Company has completed Phase III development of its product candidate, sodium zirconium cyclosilicate (ZS-9), for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed three clinical studies with ZS-9 for patients with hyperkalemia, including patients with chronic kidney disease (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS) inhibitor therapy.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201512/31/2014YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Guy P.Nohra 54 12/31/2014 12/31/2014
President, Co-Founder Alvaro F.Guillem 57 2/4/2015 1/1/2008
Chief Executive Officer, Director Robert D.Alexander 45 3/1/2014 10/1/2012
11 additional Officers and Directors records available in full report.

General Information
Stock Exchange: NASD
Federal Tax Id: 263305698
Fax Number: (650) 362-9575


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023